Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED
- Written by PR Newswire
- Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor
- Inmagene retains rights to develop and commercialize both assets worldwide
SAN DIEGO, Feb. 2, 2024 /PRNewswire/...














